Galectin Therapeutics Inc. (NASDAQ:GALT)

CAPS Rating: 1 out of 5

A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.

Results 1 - 6 of 6

Recs

0
Member Avatar superstar (99.02) Submitted: 7/30/2014 11:21:17 AM : Outperform Start Price: $7.15 GALT Score: -27.83

I liked the GALT statement issued on its GR-MD-02 Development Program. The company believes the market misinterpreted positive clinical data.

Recs

0
Member Avatar newt1322 (< 20) Submitted: 9/16/2013 11:54:30 AM : Outperform Start Price: $10.35 GALT Score: -66.11

galt is 20 years ahead of everyone else due to the smart move of bringing the lead russian scientist over and securing his 20-25 years of research and folding it into what they knew about the molecules.

Recs

0
Member Avatar adi101 (87.56) Submitted: 8/4/2013 1:42:20 PM : Outperform Start Price: $6.00 GALT Score: -29.78



Specilative

Recs

3
Member Avatar zzlangerhans (99.77) Submitted: 2/1/2013 4:51:07 PM : Underperform Start Price: $2.53 GALT Score: -74.59

Galectin must be gearing up for more dilution. I would imagine that's why they're shooting out PR's on mouse experiments and upcoming "topline" phase I data with only enough cash to get them through mid 2013. Something must be working as the stock is floating up from a low of 1.66 in November despite a complete absence of genuine positive catalysts. Perhaps Vista Partners is putting in some overtime sending out faxes.

Recs

3
Member Avatar BuffettJunior1 (96.96) Submitted: 6/2/2011 4:58:08 PM : Underperform Start Price: $7.74 GALT Score: +85.60

The only thing this company is good at is burning money. Over the past 10 years the company hasn't made a dime. I still don't understand how this garbage stock has a market cap of 100 million.

Recs

0
Member Avatar Biotoday (40.96) Submitted: 10/7/2010 11:26:17 AM : Outperform Start Price: $4.33 GALT Score: -51.11

From Accredited Investor grapevine

Results 1 - 6 of 6

Featured Broker Partners


Advertisement